Skip to content

Application of lauromacrogol in oral mucocele

Application of lauromacrogol in oral mucocele

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400089462
Enrollment
Unknown
Registered
2024-09-09
Start date
2020-08-18
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

oral mucocele

Interventions

experimental group:For minor salivary gland mucocele, 1% lauromacrogol was injected into the cyst cavity and base, and for ranula, sclerosant was injected only into the cyst cavity.
control group: A spindle shaped incision around the mucocele was made, and the mucocele and related salivary gland was removed for minor salivary gland mucocele. As for ranula, sublingual gland was re

Sponsors

Hospital of Stomatology, Wuhan University.
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients were diagnosed with salivary gland mucocele.

Exclusion criteria

Exclusion criteria: 1. Patients with oral mucosal diseases such as lichen planus, submucosal fibrosis, burning mouth syndrome, etc. 2. Patients with contraindications for treatment, such as acute severe heart diseases, endocarditis, myocarditis, heart failure, uncontrolled hypertension, uncontrolled diabetes, fever, etc. 3. Patients were unwilling to be enrolled in the study, could not cooperate with treatment or could not attend follow-up.

Design outcomes

Primary

MeasureTime frame
the diameter of lesion;

Countries

China

Contacts

Public ContactZhong Haoyan

Hospital of Stomatology, Wuhan University.

chungs1986@whu.edu.cn+86 133 8766 2210

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026